- Home
- SAR vs ENGN Comparison
SAR vs ENGN Comparison
Compare SAR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAR
- ENGN
- Stock Information
- Founded
- SAR 2007
- ENGN 1999
- Country
- SAR United States
- ENGN Canada
- Employees
- SAR N/A
- ENGN N/A
- Industry
- SAR Investment Managers
- ENGN
- Sector
- SAR Finance
- ENGN
- Exchange
- SAR Nasdaq
- ENGN Nasdaq
- Market Cap
- SAR 402.9M
- ENGN 379.3M
- IPO Year
- SAR 2007
- ENGN N/A
- Fundamental
- Price
- SAR $22.37
- ENGN $6.92
- Analyst Decision
- SAR Hold
- ENGN Buy
- Analyst Count
- SAR 4
- ENGN 7
- Target Price
- SAR $23.75
- ENGN $20.29
- AVG Volume (30 Days)
- SAR 145.8K
- ENGN 377.0K
- Earning Date
- SAR 10-07-2025
- ENGN 12-18-2025
- Dividend Yield
- SAR 13.42%
- ENGN N/A
- EPS Growth
- SAR 52.15
- ENGN N/A
- EPS
- SAR 2.38
- ENGN N/A
- Revenue
- SAR $130,118,086.00
- ENGN N/A
- Revenue This Year
- SAR N/A
- ENGN N/A
- Revenue Next Year
- SAR $1.71
- ENGN N/A
- P/E Ratio
- SAR $9.38
- ENGN N/A
- Revenue Growth
- SAR N/A
- ENGN N/A
- 52 Week Low
- SAR $21.10
- ENGN $2.65
- 52 Week High
- SAR $26.49
- ENGN $9.65
- Technical
- Relative Strength Index (RSI)
- SAR 42.47
- ENGN 42.35
- Support Level
- SAR $22.12
- ENGN $6.62
- Resistance Level
- SAR $22.59
- ENGN $8.40
- Average True Range (ATR)
- SAR 0.42
- ENGN 0.84
- MACD
- SAR 0.10
- ENGN -0.29
- Stochastic Oscillator
- SAR 61.27
- ENGN 12.78
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.